A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Gastric Cancer(ALTER0503)
Phase of Trial: Phase II/III
Latest Information Update: 03 Jan 2018
At a glance
- Drugs Anlotinib (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 27 Dec 2017 Planned End Date changed from 1 May 2017 to 1 Dec 2017.
- 27 Dec 2017 Planned primary completion date changed from 1 May 2017 to 1 Dec 2017.
- 19 Oct 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.